Congress wants FDA updates on drug safety changes
Executive Summary
Congress' FY 2005 omnibus spending bill (HR 4818) conference report chastises FDA for failing to promptly provide documents related to drug safety activities to House and Senate Appropriations Committees. "The conferees find it necessary to remind" FDA "that the committees on Appropriations perform critical oversight functions for the agency," the report states. "It is insupportable that in some cases FDA has given information about major policy matters to the press before providing the same information to Congress." The conferees request "regular progress reports" on the Institute of Medicine's review of FDA's post-marketing safety regulatory system (1"The Pink Sheet" Nov. 15, 2004, p. 8)...
You may also be interested in...
IoM Drug Safety Study May Buy Time For FDA; Report Will Play In PDUFA IV
FDA's decision to proceed with an Institute of Medicine review of drug safety regulation could trigger a full-fledged debate over the possibility of creating a separate post-marketing regulatory agency in the U.S
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.